IR Information
IR Information
News Release
News release
-
2026.07.10
Announcement Regarding the Publication of a Paper on the PC-SOD Phase III Clinical Trial Protocol
(169KB)
-
2026.07.07
Announcement of the Completion of Patient Enrollment in the Phase III Clinical Trial (Confirmatory Trial) for PC-SOD
(262KB)
-
2026.07.06
Report on participation in Bio2026
(479KB)
-
2026.06.29
Notice of Resolutions of the 24th Ordinary General Meeting of Shareholders
(96KB)
-
2026.04.07
Announcement of Joint Research Agreement with Kansai Medical University
(146KB)
Financial Information
Disclosure
Financial Results
| 24th Fiscal Period (Results for March 2026) | |
|---|---|
| Net sales (Thousand yen) |
430,451 |
| Ordinary profit (loss) (Thousand yen) |
146,733 |
| Profit (loss) (Thousand yen) |
△55,410 |
| Net assets (Thousand yen) |
5,205,960 |
| Total assets (Thousand yen) |
6,308,322 |
| Equity ratio (%) | 82.5 |
Business Report
Business report
24th Term
Business Overview
(562KB)
23rd Term
Business Overview
(544KB)
22nd Term
Business Overview
(558KB)
21th Term
Business Overview
(485KB)
20th Term
Business Overview
(568KB)
